Phase Ib study of limited androgen ablation and two dose levels of temsirolimus (NSC 683864) in patients with prostate cancer who have a biochemical relapse after prostatectomy and/or radiotherapy

Trial Profile

Phase Ib study of limited androgen ablation and two dose levels of temsirolimus (NSC 683864) in patients with prostate cancer who have a biochemical relapse after prostatectomy and/or radiotherapy

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2013

At a glance

  • Drugs Temsirolimus (Primary) ; Bicalutamide; Flutamide; Goserelin; Leuprorelin; Nilutamide
  • Indications Prostate cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 02 Jul 2010 Planned end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov
    • 01 Feb 2008 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top